Duality Advisers LP Purchases New Shares in Henry Schein, Inc. (NASDAQ:HSIC)

Duality Advisers LP bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 20,618 shares of the company’s stock, valued at approximately $1,561,000.

A number of other hedge funds have also recently modified their holdings of HSIC. Lazard Asset Management LLC boosted its holdings in shares of Henry Schein by 1,303.3% during the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock valued at $92,614,000 after buying an additional 1,158,451 shares in the last quarter. Boston Partners raised its position in Henry Schein by 4,975.9% in the 3rd quarter. Boston Partners now owns 1,080,598 shares of the company’s stock worth $80,229,000 after buying an additional 1,059,309 shares during the last quarter. American Century Companies Inc. raised its position in Henry Schein by 7.3% in the 3rd quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock worth $350,392,000 after buying an additional 322,649 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in Henry Schein in the 3rd quarter worth about $19,864,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Henry Schein in the 3rd quarter worth about $16,650,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 1.7 %

Shares of NASDAQ:HSIC opened at $72.04 on Tuesday. Henry Schein, Inc. has a 52-week low of $60.01 and a 52-week high of $85.39. The stock has a market cap of $9.26 billion, a price-to-earnings ratio of 22.87, a PEG ratio of 1.76 and a beta of 0.87. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average price of $74.30 and a 200-day moving average price of $72.44.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). The company had revenue of $3.02 billion for the quarter, compared to analysts’ expectations of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The firm’s revenue was down 10.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 earnings per share. Equities analysts predict that Henry Schein, Inc. will post 5.07 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on HSIC. Barrington Research boosted their target price on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. TheStreet upgraded Henry Schein from a “c+” rating to a “b-” rating in a research note on Monday, February 26th. Evercore ISI upped their price target on Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. upped their price target on Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Finally, Jefferies Financial Group increased their price target on Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research report on Wednesday, March 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $81.09.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares in the company, valued at $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.